HeartSciences Inc., a healthcare information technology company specialising in artificial intelligence-enabled electrocardiography, has launched MyoVista Insights™ version 1.3. The latest update introduces the MyoVista Insights AI-ECG Algorithm Marketplace, enabling third-party AI-ECG algorithms to be integrated into the platform.
The first algorithm available is Bunkerhill Health’s FDA-cleared ECG-EF model, which detects reduced left ventricular ejection fraction (LVEF ≤40%) using a routine 12-lead ECG.
The release makes an FDA-cleared AI-ECG algorithm available through the platform for healthcare organisations of all sizes across the United States, including integrated health systems, community hospitals, critical access hospitals and primary care practices.
It also provides AI developers with a commercial route to deliver cleared algorithms through a recurring software-as-a-service (SaaS) model without creating separate workflow and distribution infrastructure.
The company plans to expand the marketplace by adding more third-party FDA-cleared algorithms.
The ECG-EF algorithm supports earlier identification of patients at risk of heart failure, helping clinicians make timely referrals.
AI-assisted ECG assessments qualify for Medicare reimbursement under the Hospital Outpatient Prospective Payment System through Ambulatory Payment Classification 5734, with an estimated national payment rate of approximately US$136 per assessment in 2026.
MyoVista Insights is a cloud-based, device-independent ECG management system supporting Epic Toolbox designation, HL7v2 workflows, single sign-on and SMART on FHIR integration.
